180 related articles for article (PubMed ID: 37185873)
21. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Krug U; Koschmieder A; Schwammbach D; Gerss J; Tidow N; Steffen B; Bug G; Brandts CH; Schaich M; Röllig C; Thiede C; Noppeney R; Stelljes M; Büchner T; Koschmieder S; Dührsen U; Serve H; Ehninger G; Berdel WE; Müller-Tidow C
PLoS One; 2012; 7(12):e52695. PubMed ID: 23300745
[TBL] [Abstract][Full Text] [Related]
23. Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
Bray WM; Bivona C; Rockey M; Henry D; Grauer D; Abhyankar S; Aljitawi O; Ganguly S; McGuirk J; Singh A; Lin TL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):691-7. PubMed ID: 26231954
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Lee JH; Joo YD; Kim H; Bae SH; Kim MK; Zang DY; Lee JL; Lee GW; Lee JH; Park JH; Kim DY; Lee WS; Ryoo HM; Hyun MS; Kim HJ; Min YJ; Jang YE; Lee KH;
Blood; 2011 Oct; 118(14):3832-41. PubMed ID: 21828126
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
28. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
29. [Acute myeloid leukemia of the elderly: recent progresses in therapy].
Yamauchi T
Rinsho Ketsueki; 2018; 59(6):735-740. PubMed ID: 29973453
[TBL] [Abstract][Full Text] [Related]
30. Daunorubicin 90 mg/m
Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
[TBL] [Abstract][Full Text] [Related]
31. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Neubauer A; Maharry K; Mrózek K; Thiede C; Marcucci G; Paschka P; Mayer RJ; Larson RA; Liu ET; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4603-9. PubMed ID: 18559876
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of the safety and efficacy of 60 mg·m
Cao XX; Wang SJ; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):892-897. PubMed ID: 27801323
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
34. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
35. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
[TBL] [Abstract][Full Text] [Related]
36. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
[TBL] [Abstract][Full Text] [Related]
37. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
38. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
39. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
[TBL] [Abstract][Full Text] [Related]
40. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
